ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026

Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective.

Francois-Emery Cotté et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.